Image (7ad45dfa A630 4e5f 85c0 25dc9e8bfbb7 942 1)
Duloxetine Capsule, Delayed Release
Product Images NDC 50090-7784
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-7784). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Structure (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 01)
Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 02)
This text provides information on the proportion of patients experiencing a relapse over time in a study comparing a placebo to duloxetine treatment. The graph shows the time from randomization to relapse in days using the Kaplan-Meier estimator method. This data can be valuable for evaluating the effectiveness of duloxetine in preventing relapse compared to placebo.*
Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 03)
This text provides information on the proportion of patients experiencing relapse over time in a study comparing a placebo with Duloxetine treatment. The graph shows the percentages of patients experiencing relapse at different time points after randomization. The data was analyzed using the Kaplan-Meier estimator method.*
Figure 1 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 04)
Figure 2 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 05)
The text provides information about the percentage of patients improved in terms of pain relief from baseline when treated with different medications such as Duloxetine 60mg BID, Duloxetine 60mg QD, and Placebo. This data can be useful for evaluating the effectiveness of these medications in managing pain.*
Fig 5 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 06)
This is a comparison chart showing the percentage of patients improved with different treatments for pain. The chart compares the percentage improvement in pain from baseline for Duloxetine 60 mg taken twice a day, Duloxetine 60 mg taken once a day, and Placebo. The chart shows the levels of improvement in increments ranging from >0 to 100%.*
Fig 6 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 07)
Percentage of patients improved with different doses of Duloxetine compared to placebo is shown in the given table. The percentages range from 0 to 100, indicating the level of improvement in pain from baseline. The data suggests that Duloxetine at different doses showed higher improvement rates compared to the placebo group.*
Fig 7 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 08)
The text provides data on the percentage of pediatric patients aged 13 to 17 years old with Juvenile Fibromyalgia Syndrome who achieved various levels of pain relief at week 12 in Study FM-4. The comparison is made between Duloxetine 60mg once daily and Placebo. Duloxetine-treated patients received 30 mg once daily for 1 week and then titrated to 60 mg once daily for 12 weeks. Pain relief was measured using the Brief Pain Inventory - Modified Short Form: Adolescent Version Average Pain Score. The chart shows the percentage of patients improved across different pain relief levels.*
Figure 8 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 09)
This is a description of the percentage of patients improved with either placebo or duloxetine 60/120 mg once daily. It shows the percent improvement in pain from baseline using a graph with percentages on the x-axis and improvement levels on the y-axis.*
Figure 9 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 10)
This text provides information regarding the percentage of patients who showed improvement while taking Duloxetine 60 mg once daily compared to those who took a placebo. The graph shows the percent improvement in pain from baseline (BOCF). It appears that 100% of patients experienced improvement with Duloxetine compared to the placebo.*
Figure 10 (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 11)
This information provides the percentage of patients who experienced improvement in pain levels when treated with either a placebo or duloxetine at a dosage of 60/120 mg daily. The data shows that 100% of patients improved with duloxetine, compared to the placebo. This suggests a significant positive impact of duloxetine in managing pain.*
Image (7efa28f3 0b15 4e1c 835f 2f1dff37bee8 935 1)
Label Image (Lbl500907784)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
